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Abstract
A new transgenic mouse model for global increases in the Sodium Dependent Vitamin C transporter 2 (SVCT2) has been
generated. The SVCT2-Tg mouse shows increased SVCT2 mRNA levels in all organs tested and correspondingly increased
ascorbic acid (ASC) levels in all organs except liver. The extent of the increase in transporter mRNA expression differed
among mice and among organs. The increased ASC levels did not have any adverse effects on behavior in the SVCT2-Tg
mice, which did not differ from wild-type mice on tests of locomotor activity, anxiety, sensorimotor or cognitive ability. High
levels of SVCT2 and ASC were found in the kidneys of SVCT2-Tg mice and urinary albumin excretion was lower in these mice
than in wild-types. No gross pathological changes were noted in kidneys from SVCT2-Tg mice. SVCT2 immunoreactivity was
detected in both SVCT2 and wild-type mice, and a stronger signal was seen in tubules than in glomeruli. Six treatments with
Paraquat (3x10 and 3x15 mg/kg i.p.) were used to induce oxidative stress in mice. SVCT2-Tg mice showed a clear
attenuation of Paraquat-induced oxidative stress in lung, as measured by F2-isoprostanes. Paraquat also decreased SVCT2
mRNA signal in liver, lung and kidney in SVCT2-Tg mice.
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Introduction
In most mammals vitamin C (ascorbic acid; ASC) is synthesized
in the liver. In humans, non-human primates, and guinea pigs the
loss of action of the gulonolactone oxidase gene that is responsible for
the last step in ASC synthesis from glucose leads to dependence on
dietary intake of ASC to avoid scurvy. ASC is transported into the
blood stream, cerebrospinal fluid and cells via the action of two
specific vitamin C transporters – Sodium Dependent Vitamin C
Transporters 1 and 2 (SVCT1 and SVCT2) [1,2,3]. SVCT1 and
SVCT2 are differentially distributed among organs [3]. SVCT1 is
mainly localized to epithelial cells in kidney, intestines and liver. In
contrast, SVCT2 is highly expressed in most other tissues
including brain, lung, spleen and liver. The complete function,
location and orientation of these transporters is still under
investigation.
Several mouse models exist for the study of decreased levels of
ASC in vivo. Knockout mice have been generated to study global
ASC deficits due to lack of ASC synthesis (gulo(2/2) mice [4]),
and for tissue specific decreases due to knockout of the two ASC
transporters SVCT2(2/2) [5], and SVCT1(2/2) [6].
SVCT2(2/2) do not survive past birth and show severe
hemorrhage in brain accompanying almost undetectable ASC
levels in SVCT2-dependent organs ([5,7]. SVCT1(2/2) mice
have greatly increased ASC excretion and also exhibit increased
perinatal mortality. In contrast to these studies on decreased ASC,
and owing to the strict control exerted on ASC levels in tissues by
these transporters, it is not possible to reliably increase ASC levels
in tissues by oral supplementation alone [8], nor even by
parenteral methods [9], although short-term increases can be
seen in blood and liver following these methods. Thus, in order to
study the effects of increased ASC in tissues, and to further
delineate the role of ASC in response to endogenous and
exogenous oxidative stress, we sought to generate a mouse model
that expressed additional copies of the SVCT2. Regulation of
SVCT2 and ASC levels differ among organs [10,11] and thus an
important part of the study was to assess changes in expression of
the transporter and of ASC level in multiple organs. ASC is
generally considered for its antioxidant benefits and so the
effectiveness of increased ASC was assessed against a major
oxidative stress, paraquat. However, in high concentrations ASC
may also have a pro-oxidant effect [12] and so oxidative stress in
the mice was also measured under baseline conditions.
To our knowledge, the only similar model currently in existence
expresses additional copies of the human SVCT2 only in the eye,
owing to an eye specific promoter [12]. In these hSVCT2 mice the
higher quantities (up to approximately 10-fold) of both ASC and
its more reactive two-electron oxidized form dehydroascorbic acid
(DHA) in the lens contributed to protein damage via the Maillard
reaction. A number of advanced ascorbylation productions were
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noted to have taken on yellow brown coloring similar to that
typically observed in the aging human lens. In the present study we
sought to test the effect of systemic increases in SVCT2 and
whether any resultant increase in ASC levels would be protective
against oxidative insult or would contribute to oxidative damage as
in the Fan et al. studies. Thus, the overall aim of these experiments
was to generate a mouse that had global increases in SVCT2
expression and document the concomitant changes in ASC. We
further sought to whether increased tissue ASC would protect
against paraquat-induced oxidative stress. Data supportive of both
of these aims suggest that the SVCT2-Tg mouse will be a useful
model for the study of ASC transport and oxidative stress
processes.
Materials and Methods
Ethics Statement
All procedures were approved by the Vanderbilt University
committee for Institutional Animal Use and Care and were
conducted in accordance with NIH guidelines.
Generation of Slc23a2 Transgenic Mouse
The SVCT2 BAC clone, RP24-222C8, containing the 60kb
gene for slc23a2 and 90kb surrounding DNA was selected from
Clone Finder and purchased from Invitrogen. It was selected
because the sequences at its ends placed it in a region of the mouse
genome free of other genes. It contained ,50,000 bases preceding
the gene and so it was likely to have most or all of the promoter
sequences. The purified DNA (1 ng/ml) was microinjected into the
pronuclei of one-cell 12 h old B6D2F1 mouse embryos in the
Transgenic Mouse/Embryonic Stem cell shared resource core of
the Vanderbilt Ingram Cancer Center. Two chimeric founder
mice were obtained as determined by genotyping the progeny for
BAC vector sequence (Table 1). Two of these lines showed
increased copy number of slc23a2 as determined by qrtPCR with
actin as a reference gene. The line expressing higher levels of
SVCT2 was chosen and maintained as a colony. All mice used in
this study were back-crossed at least 9 times onto the C57Bl6
background (Jackson labs).
Slc23a2 Knock Out Mice
Mice heterozygous for a targeted (lethal) knockout of slc23a2
(SVCT2-KO(2/2)) were originally obtained from Dr. Robert
Nussbaum and are maintained as a colony in house. Homozygous
SVCT2-KO(2/2) mice survive the gestation period but do not
survive past birth and die without breathing and showing extensive
hemorrhage in the brain [5,7]. The presence of the knockout gene
was detected using a primer set which amplifies DNA spanning the
native DNA and the neomycin resistance gene belonging to the
substituted DNA (Table 1). Heterozygous mice (SVCT2-KO(+/
2)) were crossed with SVCT2-Tg mice to determine functionality
of the transgene by ability to rescue ASC levels and promote
survival in SVCT2-KO(2/2) mice.
SVCT2-Tg Mice used in Studies
Initial studies of SVCT2 expression and rescue of the SVCT2-
KO(2/2) genotype were performed with hemizygous mice. Later
lines were maintained as homozygous transgenic mice. For all
other studies reported below, adult SVCT2-Tg mice (3–6 months)
were used. Mice were bred from homozygous SVCT2-Tg males
and females and offspring were checked for presence of the BAC
gene, indicating additional copies of SVCT2. Expression amounts
varied between mice, and even among tissues in the same mouse,
so expression was determined post-mortem by RT-PCR as
described below. Group numbers are reported for each experi-
ment. The breeding schedule did not permit use of littermates as
controls, instead we used age-matched wild-type mice from the
background strain C57Bl6 that were maintained as a colony in-
house.
mRNA Extraction and Real Time PCR
Total RNA was extracted using GenEluteTM Mammalian
Total RNA Miniprep Kit (Sigma–Aldrich). Tissue samples were
homogenized with an electric homogenizer and total RNA was
extracted according to the manufacturer’s protocol. RNA
concentrations were determined relative to protein by measuring
absorbance at 260 and 280 nm, respectively. cDNA was
synthesized from RNA samples using TaqMan Reverse Tran-
scriptase (Sigma–Aldrich) following the manufacturer’s protocol.
Real time PCR (qrtPCR) was then performed to establish
transporter copy number for Slc23a2 and b-actin. Primers used
are shown in Table 1. SybrGreen (BioRad) reagent was used with
the MyIQ apparatus (BioRad).
Fluorescence in Situ Hybridization
Fluorescence in Situ Hybridization (FISH) was performed as
a service by the Van Andel institute Laboratory of Germ line
Modification and Cytogenetics in Grand Rapids, Michigan. FISH
was performed on a descendent of the transgenic line used in this
study. Chromosome pairs were identified using spectral karyotyp-
ing (SKY).
Measurement of Ascorbic Acid
ASC content of tissues, serum, and urine was determined by
HPLC according to previously published methods [9,13,14].
Briefly, weighed tissue samples were homogenized sequentially in
a combination of two solutions, 25% (w/v) aqueous metapho-
sphoric acid and 100 mM sodium phosphate buffer containing
5 mM EDTA, with a final ratio of 2:7. Serum was diluted 1:9 with
200 mM sodium perchlorate, and urine was diluted 1:20 with
90% methanol with EDTA. Samples were centrifuged and the
supernatant was taken for assay of ASC as described above
following appropriate dilution with HPLC mobile phase.
Table 1. Primer sequences used for PCR.
Target Sequence
Primers used for genotyping PCR
SVCT2 CAT CTG TGC GTG CAT AGT AGC
CAC CGT GGC CCT CAT TG
TCT GAG CCC AGA AAG CGA AG
GAT GGACGG CAT ACA AGT TC
SVCT2-Tg (BAC) Forward: GGAAATCGTCGTGGTATTCACTC
Reverse: TCCCAATGGCATCGTAAAGAAC
Primers used for RT-PCR
Slc23a2 for SVCT2-Tg Forward: AAGGATGGACGGCATACAAG
Reverse: TCTGTGCGTGCATAGTAGCC
b-actin Forward: GTTTGAGACCTTCAACACCCC
Reverse: GTGGCCATCTCCTGCTCGAAGTC
SVCT1 Forward: CAATATAGAAACTGGGTCTGTGTG
Reverse: CCAACTCAGGTCTTCTGTCTC
doi:10.1371/journal.pone.0035623.t001
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MDA was quantified as thiobarbituric acid reactive substances
(TBARS) according to previously published methods [15] as
a measure of lipid peroxidation. Briefly, weighed samples were
homogenized in 1 ml 5% trichloroacetic acid. Samples were
centrifuged and 250 ml of the supernatant was reacted with the
same volume of 20 mM thiobarbituric acid for 35 min at 95uC,
followed by 10 min at 4uC. Sample fluorescence was read using
a spectrophotometric plate reader with an excitation wavelength of
515 nm and emission wavelength of 553 nm.
Measurement of F2-isoprostanes
F2-isoprostanes were measured in the Vanderbilt Eicosanoid
core by gas chromatography/negative ion chemical ionization
mass spectrometry (GC/NICI-MS) employing stable isotope
dilution with [
2H4]-15-F2t-IsoP as the internal standard [16].
Kidney Function
Urinary albumin excretion was measured in spot urine samples
by capture ELISA using a mouse albumin quantitation kit (Bethyl,
Montgomery, TX). Urine creatinine was measured using Infinity
creatinine stable reagent (Thermo Fisher Scientific, Middletown,
VA), according to manufacturer’s protocols. Albuminuria was
expressed as urinary albumin to creatinine ratio (ACR). Portions
of mouse kidneys were fixed in buffered formalin, dehydrated
through graded ethanols, embedded in paraffin, and sections
(2 mm thick) were stained with hematoxylin and eosin (H&E).
Additional kidneys were taken from different SVCT2-Tg and
wild-type control mice and frozen in OCT medium prior to
preparation of 5 mm sections using a cryostat. Each section was
stained for SVCT2 (primary: goat Abs to SVCT2, S-19, Santa
Cruz cat. #sc-9926, diluted 1:150; secondary: donkey anti-goat
Abs Alexa Flour 488 (cat. #A11055, diluted 1:1000) and von
Willebrand factor 8 (primary: rabbit Abs to vWF, diluted 1:500;
secondary: donkey anti-rabbit Abs Alexa Fluor 594 (cat.
#A21207, diluted 1:1000)). Von Willebrand factor 8 was used
to stain for endothelial cells that lines capillaries in the glomerulus.
Staining for SVCT2 was also performed without incubation with
primary antibody to confirm specificity of staining.
Behavioral Analysis
A series of behavioral tests were conducted with 3-month-old
SVCT2-Tg (5 male and 5 female) and wild-type (5 male and
5 female) mice in order to establish whether there were any
behavioral consequences of increased SVCT2 expression.
Mice were first tested on the Elevated Zero Maze (EZM) for
anxiety as indexed by exploration of open and enclosed areas
(5 min. trial, data analyzed using AnyMaze (Noldus)). Locomotor
activity was measured by infra-red beam breaks in standard activity
chambers (32 cm
2, Med PC Associates) during two 15 min. trials
on days 1 and 3. Repeated measurements permitted measurement
of anxiety (time spent in center versus edge of chamber on initial
trial) and also of habituation to the chambers (memory for testing
environment) indexed through decreasing activity across time and
between the sessions. Alternation behavior in the Y-maze was used
as a measure of spatial working memory. Mice were permitted to
explore the Y-shaped maze for 5 min. and the number and
pattern of arm entries were noted by the experimenter. An arm
entry was counted when the whole mouse entered the arm, and an
alternation was designated as entry into each of the three arms
within three consecutive arm entries (i.e. ABC, but not BAB).
Percent alternation was calculated as alternations/(total entries –
2). Neuromuscular ability was tested on the rotorod in repeated
training sessions on three consecutive days. Three trials, up to
a maximum of 300 s per trial were administered during each
training session with an inter-trial interval of between 5 to
15 mins. During the trial, the mice attempted to remain balanced
on an accelerating rotorod (4 rpm up to a maximum of 40 rpm).
Time to the first rotation (grasping the rod and rotating along with
it instead of walking on top of it) and time to fall were noted by the
experimenter.
Treatment with Paraquat
Mice were treated with paraquat (PQ, paraquat dichloride,
Sigma, USA) in order to induce oxidative damage by elevated
levels of superoxide [17]. Mice were injected with three treatments
of 10 mg/kg followed by three further treatments of 15 mg/kg
(intraperitoneal, administration volume 10 ml/kg). This treatment
was designed to induce a chronic low level of damage. Treatments
took place on days 1, 4, 9, 12, 15, & 18 and mice were sacrificed
and tissues removed for analysis on day 19 of the study. Mouse
health was monitored daily and mice were weighed frequently
during the treatment period. Control mice were treated with the
vehicle alone, which was 0.9% saline. Following previous reports
that PQ treatment can affect activity levels and sensorimotor
abilities [18], mice were tested in the locomotor activity chambers
and on the rotorod according to methods described above.
Locomotor activity testing was conducted across a single 30-min.
session, 20-min. after PQ or saline treatment on day 15. Rotorod
testing took place 3 hours following treatments on day 15, and on
day 16 (non-treatment day). Mice included in this study were (PQ
N=5 wild-type, N=5 SVCT2-Tg; Saline N=5 wild-type, N=5
SVCT2-Tg).
Statistical Analyses
Biochemical data. Biochemical data were analyzed in Prism
5 for Mac by unpaired t-test (2-tailed) with separate analyses
conducted for each tissue type in each assay. In cases where equal
variance in data could not be assumed, Welch’s correction for
unequal variances was applied to analyses. ASC and MDA
determination were made with two separate cohorts of mice,
therefore, to ensure consistency within the results, data from the
second cohort were transformed using z-scores to normalize them
with reference to the original cohort. The same transformation
was not required for mRNA data for which each data from each
cohort were already expressed relative to wild-type. Transgene
copy number varied among mice and among tissues within each
mice, therefore, we have provided scatterplots showing data points
from each individual mouse for each measure rather than group
means.
Behavioral data. Behavioral data were analyzed with SPSS
Version 19 for Mac. For single measure tests (Y-maze, EZM, open
field), univariate ANOVA was used. In cases of repeated testing
across trials (locomotor activity, rotorod) repeated measures
ANOVA was used. Data were first analyzed with both genotype
(SVCT2-Tg; wild-type) and gender (male; female) as between-
groups factors. If there was no main effect of gender, then data
were collapsed across gender and analyses were repeated with
genotype as the only between groups factor. Where there was
a main effect of gender data are reported for male and female mice
separately.
Results
Generation of Founder Mice
After gestation in pseudopregnant females one founder mouse
was obtained. This male (Bac2) expressed a 2.260.2-fold increase
Increased Ascorbic Acid in SVCT2-Transgenic Mouse
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littermates and was used to generate the SVCT2-Tg colony used
in this experiment. The founder was bred to C57Bl/6 mice for at
least 10 generations to place the transgene on this background
before experimentation began.
Location of Transgene
FISH was used to determine the location of the transgene in one
of the lines. The BAC transgene that was passed in the germ line
was found on chromosome 9, while the native gene is on
chromosome 2 (Fig. 1). The BAC transgene was also observed to
be much brighter than the native copies, indicating higher
expression of the transgene than native copies.
Rescue of the Lethal Phenotype by the Transgene
In order to determine if the SVCT2 transgene could substitute
for the native gene, it was necessary to show two copies of the
ablated native gene in a surviving transgenic mouse. Matings
between SVCT2-Tg and SVCT2-KO(+/2) heterozygous ani-
mals were carried out. From the progeny SVCT2-Tg.SVCT2-
KO(+/2) were selected and bred together. When PCR was
performed on genomic DNA of the pups born to these parents,
four out of 18 surviving pups were confirmed as homozygous
knockouts (SVCT2-KO(2/2)) that also carried the BAC
transgene. SVCT2(2/2) do not normally survive past birth
indicating that pup lethality was rescued by the transgene. In
a final crossing, an SVCT2-Tg.SVCT2-KO(2/2) mouse was
bred to an SVCT2(+/+) wild-type mouse, 23 pups sired by this
male were all heterozygous SVCT2-KO(2/+) confirming that
the genotype of the sire was SVCT2-KO(2/2), which is the
normally lethal genotype.
Normal Post-natal Development
Pups born to two SVCT2-Tg parents were normal in
appearance. Mice from ten litters of SVCT2-Tg pups (average
litter size 5.5) and seven wild-type pups (average litter size 5.29)
were weighed every 3 days from birth to 21 days. All mice
increased in mass with age (p,0.001) but there was no main effect
of genotype (p=0.09; data not shown). Litter size was not different
from wild-type mice (p=0.86).
ASC and mRNA
Intracellular vitamin C levels are tightly controlled, so that it is
difficult to increase them by dietary intervention in mice that
synthesize their own ASC. Expression of additional SVCT2 in the
transgenic animals led to increases in ASC in organs of these mice.
These increases were significant in brain cortex, spleen, kidney,
heart and lung (p,0.05, Fig. 2A, E, G, I & K). In adrenal glands
increased ASC was seen in some of the SVCT2-Tg mice from the
first cohort in a similar pattern to other tissues described above.
However, these increases were not significant, possibly due to
lower group size or small size of tissue sample for adrenal glands
and possible contamination of samples with adipose tissue. When
additional samples were added to the sample from a separate
cohort of mice, significant differences were found between the two
genotypes (p,0.05, Fig. 2M). No differences were seen between
the groups in serum or liver ASC levels (Fig. 2C & N). Both wild-
type and transgenic mice are capable of synthesis of ASC in liver
and some regulation of synthesis may have occurred to maintain
these levels at normal.
The same tissues were assayed for mRNA expression to
determine the effect of the transgene insertion on expression of
SVCT2 mRNA. Increased SVCT2 mRNA compared to wild-type
levels was found in each of the tissues studied in some or all of the
transgenic mice leading to overall group increases in cortex, liver,
spleen, kidney, and lung (Fig. 1B, D, F, H & L). Fewer heart
samples were available for mRNA expression and the increased
copy number seen in this tissue was not significantly greater than
that seen in wild-types (p=0.089). The extent of the increase in
mRNA expression varied between mice and between organs.
Adrenal gland was not studied owing to small sample size.
Of particular interest is that SVCT2 mRNA expression level
and tissue ASC level were related in some but not all tissues.
Significant correlations between mRNA level and ASC concen-
tration in the same mice were found in spleen (r=0.585, p,0.01),
lung (r=0.496, p,0.05), and kidney (r=0.687, p,0.001). The
relationships between mRNA level and ASC were also positive,
but not significant in cortex, liver, and heart (p.0.11).
Oxidative Damage in SVCT2-Tg Mice
We first quantified MDA as TBARS in tissues from SVCT2-Tg
and wild-type mice to establish whether additional ASC in tissues
could act as a pro-oxidant. We found no differences in MDA level
in the majority of the tissues tested, and in fact there was the
suggestion of a protective effect of ASC in the kidney (Fig. 3 A, C,
E-H). However, MDA levels were slightly, but not significantly,
increased in the liver of SVCT2-Tg mice. In order to further
quantify oxidative damage in these mice using a more specific
Figure 1. Fluorescent In Situ Hybridization for SVCT2. FISH analysis localized the SVCT2 transgene to one copy of chromosome 9 (#9),
whereas the native version was found on both copies of chromosome 2 (#2). Brighter signal indicates multiple copies of the transporter at the
insertion site.
doi:10.1371/journal.pone.0035623.g001
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F2-isoprostanes in brain and liver of six SVCT2-Tg and five wild-
type mice. An apparent increase in cortex F2-isoprostanes in
SVCT2-Tg mice was mostly driven by two of the six mice and the
difference was not significant (p=0.13, Fig. 3B). We verified the
ASC and SVCT2 mRNA levels of these mice to establish whether
there was a direct relationship between SVCT2 expression and F2-
isoprostanes level. However, in the cortex the ASC and mRNA
levels were within the middle range group and were actually
within normal wild-type levels. A more modest but less variable
increase in F2-isoprostanes in the liver was significant (p,0.001,
Fig. 3D), supporting the result found with MDA.
SVCT1
To assess whether compensatory mechanisms may be in place
to explain the lack of change of ASC in the liver under baseline
and PQ-treatment conditions, we assessed SVCT1 mRNA levels.
SVCT1 expression was also studied in the kidney, which also
expresses both SVCT1 and 2, but which showed increased ASC in
SVCT2-Tg mice. Neither liver nor kidney differed in SVCT1
mRNA expression according to genotype (p.0.17, data not
shown).
Kidney Function
ASC metabolism is generally well controlled in the body with
excess ASC being excreted in the urine. Reabsorption of ASC in
the kidney is the responsibility of SVCT1. SVCT2-Tg mice have
higher organ levels of ASC, but not higher plasma ASC. We
therefore determined ASC excretion to ascertain whether
additional excretion of ASC was a mechanism by which the mice
were regulating circulating levels. ASC excretion was calculated
relative to creatinine to account for any difference in mouse water
intake prior to the sample acquisition. As has previously been
reported [6] female mice excreted less ASC than male mice,
Figure 2. Ascorbic acid and mRNA level in SVCT2-Tg mice. SVCT2-Tg had higher ASC levels in all organs measured except liver, nor did serum
ASC vary between groups. (A) cortex, (C) liver, (E) spleen, (G) kidney, (I) heart, (K) lung, (M) adrenal gland, and (N) serum. mRNA signal was increased in
all organs measured, although this difference was not significant in heart. (B) cortex, (D) liver, (F) spleen, (H) kidney, (J) heart, (L) lung, (M) adrenal
gland, and (N) serum. *, **, *** p,0.05, 0.01, 0.001 compared to wild-type controls.
doi:10.1371/journal.pone.0035623.g002
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There was no difference between wild-type and SVCT2-Tg mice.
However, urinary albumin excretion was significantly lower in
SVCT2-Tg mice of both genders (p,0.01; Fig. 4B). Although
both wild-type and SVCT2-Tg mice were within the normal range
for albumin in the urine, this result suggests potentially improved
kidney function in the SVCT2-Tg mice.
Careful analysis was made of H&E stained kidney sections from
male SVCT2-Tg and wild-type mice by an experienced renal
pathologist. No evidence of any gross pathological differences was
found in the SVCT2-Tg mice (Fig. 4C). Additional frozen sections
of kidney from a different set of mice were stained with antibodies
for vWF and SVCT2 for localization of the SVCT2. Glomeruli
can be clearly seen as areas of greater staining for vWF (Figure 5,
arrows) with dense nucleation in both wild-type and SVCT2-Tg
mice. SVCT2 staining did not co-localize with vWF and was
higher in non-glomerulus areas, suggesting its presence in tubules.
SVCT2 mRNA and vitamin C level were confirmed to be higher
than wild-type in the SVCT2-Tg mice used for fluorescent
immunohistochemistry (1.94, 6.97, and 7.70 fold wild-type
expression; wild-type ASC 0.61+0.17, SVCT2-Tg
1.60+0.31 mmol/g). Staining was not formally quantified, howev-
er, no differences in signal strength or distribution were noted
between wild-type and SVCT2-Tg mice.
Behavioral Phenotype
Behavioral data are reported for 10 mice of each genotype with
equal numbers of male and female mice in each group. SVCT2-Tg
mice were normal compared to wild-type controls on each of the
measures. Exploration of the EZM (distance travelled) and percent
time spent in open areas did not differ between the genotypes or
according to gender (ps.0.077; Fig. 6Ai, ii). Distance traveled in
locomotor activity chambers decreased across the 5-min. time bins
within each 15-min. session (p,0.001) and between the two test
sessions(p,0.001),butdidnotvaryaccordingtogenotypeorgender
(ps.0.56; Fig. 6Bi) indicating normal locomotor activity and
habituation processes in the SVCT2-Tg mice. Locomotor activity
datawerealsoanalyzedtoestablishtimespentanddistancetravelled
in the center portion of the chamber versus the edge and corners
during the first 5 minutes in the novel environment as a further
measure of anxiety (open field measurement). The center portion
comprised 46% of the total area of the chamber wild-type and
SVCT2-Tgmicespentonly24%and28%oftheirtimerespectivelyin
thecenterportion.Neithertimespentincenternordistancetravelled
in center varied according to gender or genotype (ps.0.195;
Fig. 6Bii). In the Y-maze, female mice made more arm entries than
male mice (p,0.05) and SVCT2-Tg mice made more entries than
wild-type mice (p,0.01; Fig. 6Ci) but allmice performed within the
normalrangeforthistest.Therewasnointeractionbetweengender
Figure 3. Oxidative stress in SVCT2-Tg mice. Oxidative stress was quantified as malondialdehyde (TBARS) in (A) cortex, (C) liver, (E) spleen, (F)
kidney, (G) heart, and (H) lung, and as F2-isoprostanes in (B) cortex, and (D) liver). *** p,0.001 compared to wild-type controls.
doi:10.1371/journal.pone.0035623.g003
Figure 4. Kidney Function in SVCT2-Tg mice. Excreted (A) ASC and (B) albumin were measured in urine samples with the results normalized to
creatinine. Data shown are mean+S.E.M for wild-type and SVCT2-Tg mice separately for male (white bars) and female (purple bars) mice. ** p,0.01
compared to wild-type control. N=526 mice per group. (C) 2 mm sections stained with hemotoxylin and eosin (H&E) for comparison between
genotypes. Glomeruli, proximal tubules and distal tubules are all clearly visible but no changes were observable in SVCT2-Tg mice (right panel)
compared to wild-types (left panel). Images taken at 20X magnification.
doi:10.1371/journal.pone.0035623.g004
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themaze,alternationbehaviordidnotvaryaccordingtogenotypeor
gender(ps.0.36;Fig.6Cii)indicatingintactspatialworkingmemory
in the SVCT2-Tg mice. All mice had normal sensorimotor abilities
and learned to perform well on the rotorod, as shown by increasing
trial times across the three test sessions (ps,0.001; Fig. 6D). There
werenoeffectsofgenderorgenotypeonperformanceintimetofirst
rotation or to fall (ps.0.233).
Figure 5. SVCT2 location in kidney. 5 mm frozen kidney sections were stained for von Willebrand factor (VWF, red) and for SVCT2 (green) with
non-specific stain for nuclei (blue) in wild-type (left panels) and SVCT2-Tg (right panels) kidneys. Heavier staining for VWF is observed in glomeruli
(arrows) with corresponding areas of low staining for SVCT2 and high density of nuclei. A merged image (bottom panels) confirms lack of overlap of
SVCT2 and VWF in glomeruli. Images taken at 20X magnification.
doi:10.1371/journal.pone.0035623.g005
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To investigate the possibility of a protective role of elevated
ASC in response to elevated superoxide levels, mice were treated
with paraquat. Continuous monitoring during the treatment time
revealed very little loss of weight in the treated mice (p.0.15, data
not shown). Following previous reports that PQ treatment can
affect activity levels and sensorimotor abilities, mice were tested for
changes in locomotor activity and sensorimotor abilities on the
Figure 6. Normal behavior in SVCT2-Tg mice. Wild-type (white bars, black circles) and SVCT2-Tg mice (red bars, red squares) did not differ on
any of the behavioral measures conducted. (A) Elevated zero maze for (Ai) distance travelled and (Aii) percent time in open zones, (B) locomotor
activity (Bi) time traveled during two 15-min. sessions, and (Bii) time spent in the central portion of the maze during the first 5-min., (Ci) entries and
(Cii) alternation in the Y-maze, and (D) time taken to fall or rotate on the rotorod. Data shown are mean+S.E.M. N=10 mice per group.
doi:10.1371/journal.pone.0035623.g006
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activity chambers (p,0.001), but there was no main effect of
group and no group X time bin interaction (ps.0.21). In contrast
to earlier reports [18], neither task revealed any effect of PQ, and
neither was there any difference in response between the
genotypes (data not shown).
ASC and mRNA were measured in the four organs thought
most likely to be affected by PQ treatment. In contrast to earlier
results, ASC levels were higher in SVCT2-Tg mice than wild-
types in the cortex but this difference was not significant
(p=0.097; Fig. 7A). As reported above, neither were liver ASC
levels significantly greater in SVCT2-Tg mice (p=0.067; Fig. 7B).
ASC levels were increased as expected in lung and kidney of
SVCT2-Tg mice (ps,0.05; Fig. 7E, G). Analysis of SVCT2
mRNA revealed some unexpected differences among the tissues.
In the brain there were higher levels of SVCT2 mRNA in the
SVCT2-Tg mice (P,0.001), and no effect of PQ (p=0.66;
Fig. 7B). In the liver, lung and kidney, there was a significant main
effect of genotype on mRNA expression in each organ (ps,0.05;
Fig. 7D, F & H). There were also significant main effects of PQ
treatment in kidney and lung (ps,0.05). We had decided a priori to
assess the effect of PQ separately in each genotype because we
expected a different response in the SVCT2-Tg mice, and this was
performed with Bonferroni-corrected pairwise comparisons. PQ-
treated SVCT2-Tg mice had lower SVCT2 expression than saline
treated mice in liver, kidney and lung (ps,0.05; Fig. 7D, F & H),
but the same effect was not seen in the wild-type mice (ps.0.43).
Oxidative stress in response to paraquat damage was assessed in
the organs typically most affected by PQ treatment, lung and
kidney, and also in the liver, which is responsible for metabolizing
the drug. In the liver there was no increase in F2-isoprostanes
following PQ treatment (p=0.34), but there was also no difference
according to genotype (p=0.11; Fig. 8A). Expected increases in
F2-isoprostanes were seen in lungs from PQ-treated mice
(p,0.001). Bonferroni corrected pairwise comparisons were
conducted following a significant Treatment6Genotype interac-
tion from the omnibus ANOVA (p,0.05). Although PQ treatment
increased F2-isoprostanes in both genotypes, the magnitude of the
effect was much greater in wild-type (p,0.001) than SVCT2-Tg
mice (p,0.05). Additional copies of SVCT2 did not affect F2-
isoprostanes in saline-treated mice, but conferred significant
protection in the case of PQ treatment (p,0.001; Fig. 8B). A
small, but not significant, increase in F2-isoprostanes was observed
in kidney from SVCT2-Tg mice (p=0.097; Fig. 8C). Lower
numbers of PQ-treated wild-type samples mean that it is difficult
to interpret these data but overall there were no main effects of
treatment or genotype in the kidney, and no interaction between
the factors (ps.0.09).
Discussion
The data we present demonstrates successful generation of a new
mouse model that expresses functional additional copies of the
SVCT2. Incorporation of the transgene in the founder line was
shown by FISH to be in chromosome 9, rather than the native
gene that is found in chromosome 2. The strong relation between
the elevated mRNA expression in all tissues assayed, and ASC
levels in all tissues except liver, demonstrate that the transgene led
to functional copies of the transporter. This was further confirmed
by the rescue of the lethal SVCT2(2/2) genotype in breeding
studies. There was no detectable change in SVCT1 mRNA
expression indicating a lack of compensatory mechanisms.
However, we did not measure SVCT1 protein levels and nor
did we assess transporter activity for SVCT1 and SVCT2 and thus
it is possible that there are compensatory mechanisms that were
not reported here. We did not measure gulonolactone oxidase
activity, but it is unlikely that there was any large change in ASC
synthesis because neither serum ASC levels, nor liver ASC levels
differed between the groups.
Urinary ASC concentrations were similar in SVCT2-Tg and
wild-type mice, suggesting that renal reabsorption of ASC was not
affected. Early reports about the distribution of SVCT2 did not
include the kidney [1] or indicated that it was present in very low
levels [3]. The two-fold higher amounts of ASC observed in the
kidney of SVCT2-Tg mice fit with strong mRNA and protein
signals in both SVCT2-Tg and wild-type mice. Immunohistolo-
gical staining of kidneys also revealed a strong signal for SVCT2 in
both wild-type and SVCT2-Tg mice in a similar distribution. This
immunostaining occurred in areas of the kidney outside the
glomeruli, since it did not co-localize with von Willibrand factor.
Absence of the SVCT2 in glomerular endothelial cells is perhaps
surprising, since in most other vascular beds excepting the blood-
brain barrier, ASC is highly expressed in endothelial cells [3,19].
However, even in these beds, ASC is transferred from the blood to
tissues by going around and not through the endothelial cells [20].
This, and the fenestrated nature of the renal glomerular
endothelium, suggests that ASC movement from blood to urine
is not retarded by the endothelial cells. Rather, the presence of the
SVCT2 in what are likely tubular epithelial cells mirrors that of
the SVCT1, which is needed for ASC reabsorption from the urine
[6]. Although further studies of cellular localization of the SVCT2
in the kidney are needed, the non-glomerular location of SVCT2
could reflect a situation similar to that found in intestinal epithelia,
in which the SVCT1 is localized to the brush border and SVCT2
to the basolateral border of the cells [21].
Although both wild-type and SVCT2-Tg mice were within the
normal range for albumin in the urine, the lower levels of albumin
in the urine from SVCT2-Tg mice suggests potentially improved
kidney function in the SVCT2-Tg mice. There is evidence that
ASC can decrease albuminuria in kidney diseases associated with
oxidative stress (e.g. diabetes [22]) and our results suggest that this
may be linked to function of the SVCT2.
In SVCT2(+/2) mice lower ASC levels are associated with
neuromuscular weakness linked to hypomyelination and decreased
collagen of sciatic nerves [23]. Muscular weaknesses and oxidative
stress have also been seen in gulo(2/2) mice with decreased ASC
levels [24]. We sought also to document any other functional
changes resulting from the increase in ASC. Behaviorally the mice
were normal with no change in exploratory or anxiety behaviors
and no deficits or advantage in sensorimotor skills.
In initial studies there was an indication that SVCT2-Tg mice
may be under elevated oxidative stress in liver as measured by F2-
isoprostanes. This result could have offered a partial explanation
for the lack of increase in ASC in this organ, but the result was not
duplicated in the saline treated SVCT2-Tg mice in the PQ study.
On the contrary, additional copies of the SVCT2-Tg were
protective against oxidative stress in the lung induced by PQ
treatments. Daily doses of PQ in rats caused specific and severe
damage that was greatly reduced by concomitant administration
of ASC when both were given intraperitoneally [17]. Oral vitamin
C also limited acute kidney damage in patients exposed to acute
PQ poisoning [25]. For the present study we chose a low dose of
PQ and treated for just 6 days out of 21 to generate a mild
oxidative stressor. This treatment schedule likely accounts for the
lack of damage observed in the kidneys in these mice, particularly
given the ability of all of the mice in the study to synthesize their
own ASC in order to help offset such an oxidative stress, even in
wild-type mice. In addition, the background strain, C57Bl6, is
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particularly damaging to lung. This is partly because exposure is
often by inhalation, but also because PQ accumulates in the lung
and thus causes local damage through redox cycling and
production of reactive oxygen species [27]. In wild-type mice
PQ induced a large increase in F2-isoprostanes that was
substantially decreased in the SVCT2-Tg mice. It is likely that
the additional ASC available in the SVCT2-Tg mice helped to
combat this increase in reactive oxygen species. Lung ASC levels
were not significantly lowered by PQ treatment in the SVCT2-Tg
mice but the SVCT2-Tg mice had a 1.5-fold increase in ASC over
wild-type mice.
Figure 7. Ascorbic acid and mRNA levels following paraquat treatment. ASC was increased in (A) cortex, (C) liver, (E) lung, and (G) kidney,
although this difference was only significant in lung and kidney. SVCT2 mRNA was significantly higher in SVCT2-Tg mice in (B) cortex, (D) liver, (F)
lung, and (H) kidney, but significant decreases were found in PQ-treated mice compared to saline treated SVCT2-Tg mice. *, *** p,0.05, 0.001
different from wild-type control; +PQ-treated mice different from saline-treated mice of same genotype. Data shown are mean+S.E.M for wild-type
and SVCT2-Tg mice treated with saline (white bars) and paraquat (blue bars). N=5 mice per group.
doi:10.1371/journal.pone.0035623.g007
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mRNA signal was significantly decreased in the PQ treated mice
in lung, kidney and liver, but not brain. In the case of lung,
SVCT2-mRNA expression did not differ from wild-type although
ASC levels were higher. The same result was not seen in the cortex
arguing against the idea that the PQ mouse group happened by
chance to have lower expression than the saline treated controls.
Had this been the case then ASC levels would likely have been
lower as well as suggested by correlative data from initial
experiments in untreated mice. These intriguing data suggest
a complicated response of the SVCT2 to oxidative stress that may
be linked to changes in both function and amount of the
transporter. SVCT2 has been shown to develop in culture in
cortical endothelial cells [28], to be regulated by antioxidant status
in C2C12 myotubules [29] and to change in response to low ASC
in osteoblasts [30], and in liver but not cortex in in vivo studies in
gulo(2/2) mice [10]. We repeatedly observe that brain SVCT2
levels are more tightly controlled than peripheral tissues,
reinforcing the importance of ASC in the brain. This complex
response pattern is clearly an area that deserves additional study.
We propose that this mouse will be of use in studies that require
increases of ASC at the cellular level. Supplementation of mice
with oral ASC, particularly wild-type mice that can synthesize
their own ASC, does not lead to long-term increases in tissue ASC,
and particularly not in the brain, which is under tight regulation.
This new model can therefore be of use in disease models, and to
study the role of ASC in response to pharmacological agents. The
mouse may be particularly useful in studies of lung and kidney
disease in which tissues showed particularly large increases in
ASC. By crossing different models together it will also be possible
to investigate further the role of high, and in combination with the
SVCT2(+/2) mouse, low ASC in diseases with a genetic basis.
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